LONDON - Global law firm Reed Smith has advised Global Healthcare Opportunities (GHO), the European specialist investor in healthcare, and FairJourney Biologics, on all aspects of the combination of the business operations of FairJourney Biologics with UK based antibody discovery company, Iontas Limited.

FairJourney’s combination with Iontas creates a leading global antibody discovery CRO with an international footprint.

The Reed Smith team that advised on the matter was led by corporate and life sciences partner Iqbal Hussain, supported by PE partner, Mark Pedretti, tax partner Gareth Amdor, IP partner Jonathan Radcliffe and associates James Hatchard, Alia Khalil, Yexi Tran and Lily Wu.

Iqbal Hussain, partner at Reed Smith, said: “This is the second deal that we have supported GHO on this year. We are very pleased and proud to have been retained once again by the excellent GHO and FairJourney team. Reed Smith has a core focus on the life sciences industry and this deal highlights the collective strengths of the firm’s corporate and life sciences capabilities in advising on what was a complex and technical transaction in challenging times.”